Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
well put
citation for the 12 months to release TLD? I’ve seen that thrown around but never seen it backed up
where did the information that DI said we're in peer review originate from? what was the exact quote?
did DI really confirm that we’re in peer review? to me, that’s breaking silence because it implies acceptance in a journal.
process is draft submission -> acceptance in journal -> peer review -> final manuscript submission -> publication
no? i mean it’s good news and means we really are very close to seeing TLD, just seems odd he’d disclose this
never saw the answer to this as it was deleted
have you bought yet ex? genuinely curious
whatever, the SAP and new endpoints account for psPD now, and that's all that matters. of course things could have been smoother with a better design at the start. hindsight.
what matters now is that we'll pass primary and secondary with support from publication and share price will rocket. taking longer than anyone hoped but it'll happen and you know it.
nice recap, but imo your timeline is so off as to create another setup for disappointment. Sawston may well take until late January, publication + TLD could take until March or April, and approval might now happen until fall 2022 or sometime 2023. I have high confidence that things will play out as we expect, but I think it will take significantly longer than the timeline you’ve painted here.
I only say this so that when Jan/Feb rolls around with no big updates, there’s not another collective sense of dismay when in fact things are still going according to the (very slow but sure) plan.
i also find it hard to believe, with all those involved, that there’d be zero leak. $1 share price would mean zero leak. it’s surely a no-go on SNO.
but i’m still confident we’ll get positive results this winter, and $1 is a great buy price.
I don’t think any big players or even most retail investors actually expect anything at SNO, else we would be much higher than $1.04. When folks expected something at the last ASM/ASCO, there was a huge run to $2+, with the letdown and fall afterwards. No SNO run with no real expectation, and no real letdown or fall after imo.
what will it take for you to sell and move on with your life
he supposedly parsed out what would’ve been the control group by approximating it based on IMUC’s control. so he did his best to tease apart the ITT and placebo. But yeah the data would’ve matured which will help the tail, but still seems very close, which is why i’m confused at the responses the video got
no explanations for the apparent contradiction here?
senti/flipper/ other confident longs, help me see why there's no discrepancy in your thinking between senti's stickied post that says "The odds of them failing their primary and secondary endpoints are practically nil... especially with regards to the primary" and alphapuppy's video (
never mind
Why not Market Value of Listed Securities Standard, requiring closing price of $2, described on page 11 here: https://listingcenter.nasdaq.com/assets/initialguide.pdf
we just got a PR two weeks ago. sell if you’re not confident.
I’m in the same camp
Well, here’s the real reason for the Sawston delay. Thank you.
agreed. if people actually believed we’d get TLD next week, share price would be waaay higher.
I don’t think there’s any issues with the SAP or buy-in—that process took over a year and they wouldn’t have locked data without that being a shut case.
The reason for delay is likely that articles like this take an average of a year to publish, and a complicated trial like ours might take a bit longer. But, we’re within the likely range now, as it’s been about a year exactly from when they likely got data back from statisticians. In the meantime, FDA has been growing friendlier, manufacturing has been ramping up, Lancet article supports our strategy, the large loan repayment is behind us, etc etc.
I expect TLD, publication, and Sawston certification by end of January at the latest. If none of those three things happen by then I will consider shedding shares.
In three months max share price should be $4+, so I hardly care if we hit $1 again or even 87¢.
and the list of speakers hasn’t been changed since then?
can you provide a bit more to back that up?
huh? I see no mention of her
I hope Dave Innes sees this
sounds nice, but how does that jive with mgmt/DI saying they’re not releasing TLD at a conference and LL not being listed as a speaker?
Michael Bigger 11:07 pm EST tonight:
Pondering this equation Joe Burnett + Linda Liau + then some^1000 ... $CLPT $NWBO #DCVax #fireworks
Pondering this equation Joe Burnett + Linda Liau + then some^1000 ... $CLPT $NWBO #DCVax #fireworks
— Michael Bigger (@biggercapital) November 3, 2021
that wouldn’t include any naked shorting, right?
well, it's progress. slow, positive progress.
do you not see a connection between human cellular material and DCVax
okay this one you can bold
what makes you think this is algo buying?
ps no need to bold all of your posts
The high volume warrant shedding should be coming to an end. It was not a coincidence that many expired Nov 1, and a loan was due Nov 1. We survived the payback without closing under $1, and are now in the clear. Sawston, TLD, and blue skies ahead.
Warrant unloading to repay loan will likely continue through this week, then slow considerably along with the constant downward pressure. Should start to climb back up slowly middle of next week. Then Sawston and TLD on the menu for Nov-Dec.
NWBO only please